Ultragenyx Pharmaceutical (RARE) Share-based Compensation Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -34.72% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 4.80% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 10.78% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.55% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.65% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -90.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.21% |
| Dec 31, 2025 | 8.47% |
| Sep 30, 2025 | 1.15% |
| Jun 30, 2025 | 2.49% |
| Mar 31, 2025 | -88.92% |
| Dec 31, 2024 | 14.38% |
| Sep 30, 2024 | 15.48% |
| Jun 30, 2024 | 13.19% |
| Mar 31, 2024 | 14.97% |
| Dec 31, 2023 | 13.64% |
| Sep 30, 2023 | 19.69% |
| Jun 30, 2023 | 15.64% |
| Mar 31, 2023 | 16.60% |
| Dec 31, 2022 | 14.30% |
| Sep 30, 2022 | 21.56% |
| Jun 30, 2022 | 17.33% |
| Mar 31, 2022 | 13.27% |
| Dec 31, 2021 | 8.36% |
| Sep 30, 2021 | 9.31% |
| Jun 30, 2021 | 11.53% |
| Mar 31, 2021 | 8.93% |
| Dec 31, 2020 | 5.33% |
| Sep 30, 2020 | 5.79% |
| Jun 30, 2020 | 10.09% |
| Mar 31, 2020 | 11.60% |
| Dec 31, 2019 | 13.24% |
| Sep 30, 2019 | 13.28% |
| Jun 30, 2019 | 26.93% |
| Mar 31, 2019 | 25.55% |
| Dec 31, 2018 | 30.48% |
| Sep 30, 2018 | 37.81% |
| Jun 30, 2018 | 56.63% |
| Mar 31, 2018 | 98.37% |
| Dec 31, 2017 | 113.75% |
| Sep 30, 2017 | 118.28% |
| Jun 30, 2017 | 160.87% |
| Mar 31, 2017 | 163.22% |
| Dec 31, 2016 | 300.97% |
| Sep 30, 2016 | 477.77% |
| Jun 30, 2016 | 288.64% |
| Mar 31, 2016 | 276.79% |